Student worksheet: reading the weight-management trial comparison

Version 1.1.0 (2026-11-14), written against Flagship Weight Management 1.4.0. Every source link names a version and keeps returning the record you were given. AI-assisted source verification; human review none recorded. Not medical advice.

Name:  

Date:  

What you will practice

  • Tell a head-to-head trial from two separate placebo-controlled trials, and say why their numbers cannot be subtracted.
  • Read population, comparator, endpoint, time point and uncertainty from a source record instead of a headline.
  • Explain what an estimand is and why two analyses of one trial can give different percentages.
  • Cite a result with its version and reopen the exact record, including after the record was updated.

Start from the comparison page. Answer in your own words and quote a number only with its source. (or use your browser’s Print command).

  1. Question 1

    Open the five results. For each, write whether the two drugs were compared with each other inside one randomized trial. Which result is the only one that does so?

    Sources: SURMOUNT-5 (phase 3b, open-label), record surmount-5-weight-72w, release 1.4.0 · STEP 1 (double-blind), record step-1-weight-68w, release 1.4.0 · SURMOUNT-1 (phase 3, double-blind), record surmount-1-weight-72w, release 1.4.0 · Retatrutide phase 2 (double-blind), record retatrutide-phase2-weight-48w, release 1.4.0 · Rodriguez and colleagues, JAMA Internal Medicine 2024: cohort study, not a randomized trial, record jama-intern-med-2024-realworld, release 1.4.0

    Related claim checks: Check a claim: when weight-loss results can be compared · Check a claim: tirzepatide and semaglutide in the same trial

  2. Question 2

    A classmate says: "Tirzepatide beat semaglutide by 6.5 percentage points." Find the numbers in SURMOUNT-5. Where does 6.5 come from, and which design makes the subtraction allowed?

    Sources: SURMOUNT-5 (phase 3b, open-label), record surmount-5-weight-72w, release 1.4.0

    Related claim checks: Check a claim: tirzepatide and semaglutide in the same trial

  3. Question 3

    The same classmate then subtracts the STEP 1 semaglutide result from the SURMOUNT-1 tirzepatide result and says it "proves the same thing". Write down the population, follow-up and comparator of each. Is the subtraction valid? Why or why not?

    Sources: STEP 1 (double-blind), record step-1-weight-68w, release 1.4.0 · SURMOUNT-1 (phase 3, double-blind), record surmount-1-weight-72w, release 1.4.0

    Related claim checks: Check a claim: when weight-loss results can be compared

  4. Question 4

    Read the estimand for SURMOUNT-1. In your own words, what question does the displayed number answer? Then open the 1.0.0 version of the same result and write down what it said about the analysis plan.

    Sources: SURMOUNT-1 (phase 3, double-blind), record surmount-1-weight-72w, release 1.4.0 · SURMOUNT-1 (phase 3, double-blind), record surmount-1-weight-72w, release 1.0.0

    Related claim checks: Check a claim: when weight-loss results can be compared

  5. Question 5

    SURMOUNT-5 reports tirzepatide −20.2% with a 95% interval of −21.4 to −19.1. What does the interval tell you, and what does it not tell you?

    Sources: SURMOUNT-5 (phase 3b, open-label), record surmount-5-weight-72w, release 1.4.0

    Related claim checks: Check a claim: tirzepatide and semaglutide in the same trial

  6. Question 6

    The JAMA Internal Medicine cohort found tirzepatide users more likely to reach 5%, 10% and 15% weight loss. Name two reasons this is weaker evidence for "tirzepatide works better" than SURMOUNT-5, then name one thing it can still add.

    Sources: Rodriguez and colleagues, JAMA Internal Medicine 2024: cohort study, not a randomized trial, record jama-intern-med-2024-realworld, release 1.4.0

    Related claim checks: Check a claim: when weight-loss results can be compared

  7. Question 7

    Copy the citation for SURMOUNT-5 from its record page. Open the versioned-record address in a private browser window. Write down the release version and the resultsSha256 shown, then open the same address with version=1.0.0 and note what the response says about the current version.

    Sources: SURMOUNT-5 (phase 3b, open-label), record surmount-5-weight-72w, release 1.4.0 · SURMOUNT-5 (phase 3b, open-label), record surmount-5-weight-72w, release 1.0.0

    Related claim checks: Check a claim: trial registration versus posted results

  8. Question 8

    How did SURMOUNT-5 and the retatrutide phase 2 trial handle people who stopped taking the study drug? Write one sentence for each. Then say what the registry participant flow does and does not tell you about stopping the drug.

    Sources: SURMOUNT-5 (phase 3b, open-label), record surmount-5-weight-72w, release 1.4.0 · Retatrutide phase 2 (double-blind), record retatrutide-phase2-weight-48w, release 1.4.0

    Related claim checks: Check a claim: when weight-loss results can be compared

  9. Question 9

    A classmate writes: "Tirzepatide caused more weight loss than semaglutide, because its trial showed a bigger percentage." (a) Write two sentences about SURMOUNT-5 that are supported by the record and say nothing more. (b) Which verdict from Peptide Claims & Evidence fits the classmate's sentence: Supported within scope, Overstated, Insufficient evidence or Contradicted by evidence? Explain in one sentence, then open the claim check and compare.

    Sources: SURMOUNT-5 (phase 3b, open-label), record surmount-5-weight-72w, release 1.4.0

    Related claim checks: Check a claim: when weight-loss results can be compared · Check a claim: tirzepatide and semaglutide in the same trial

Instructors: faculty guide · rubric · instructor key · walkthrough